| Revenue growth | FY26 income ₹4,488cr (+7.6% YoY); Q4FY26 (+11.2% YoY). |
|---|---|
| Margins | Adj. EBITDA margin improved to 12.0% in FY26. |
| Demand visibility | 200Mn Euro CDMO contract provides long-term revenue visibility. |
| Management confidence | Strong confidence in European CDMO and Zambia JV execution. |
Growth
FY26 Revenue up 5.8% to ₹4,359cr; Adj. PAT up 27.3% to ₹276cr.
Outlook
FY28 European CDMO supplies start; Zambia facility operational FY29; expansion into Oncology/Steroid lines.
Risks
API price erosion, prolonged low domestic volume growth, and losses in trade generics/API segments.
Earnings Call filed with BSE, NSE: AKUMS. Summary written with AI assistance from the document.
Akums Drugs & Pharmaceuticals Ltd: key numbers
- Share price
- ₹821.50
- Market cap
- ₹12,930 Cr
- Revenue (annual)
- ₹4,359 Cr
- Net profit (annual)
- ₹255.2 Cr
- P/E (TTM)
- 44.3×Sector 47.4×
- Promoter holding
- 75.26%+0.00% QoQ
- FII holding
- 1.91%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Akums Drugs & Pharmaceuticals Ltd
All →Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals received an ESG rating of 65 for FY2025-26 from NSE Sustainability Ratings & Analytics Limited. The rating was assigned voluntarily based on publicly available information.
Akums Drugs & Pharmaceuticals Other Announcement
Akums Drugs and Pharmaceuticals Limited has cancelled its participation in the Antique Healthcare Investor Conference scheduled for August 25, 2026, due to unavoidable medical reasons.
Akums Drugs & Pharmaceuticals Earnings Call Transcript: Key Takeaways
Akums reported strong Q1FY27 performance with 13.9% revenue growth and 56.1% PAT increase. Results were driven by a robust 18.6% growth in the CDMO segment and improved API pricing.
Akums Drugs & Pharmaceuticals Other Announcement
The company filed its quarterly shareholding pattern for the period ended September 30, 2025, in compliance with SEBI LODR regulations.
Akums Drugs & Pharmaceuticals Investor Presentation: Key Takeaways
Akums reported strong Q1 FY27 results with 13.9% revenue growth and 56.1% PAT growth. Strategy focuses on CDMO volume growth and expanding skincare/wellness via the Oriflame India manufacturing acquisition.
Akums Drugs & Pharmaceuticals Results Update
Akums Drugs reported Q1 FY27 consolidated revenue of ₹1,167 crore, reflecting 13.9% year-on-year growth. PAT rose to ₹101 crore compared to ₹65 crore in Q1 FY26.